Using the Kaplan–Meier survival curves and log-rank tests, we compared the estimates of clinical outcomes among different molecular subtypes (Figure 1a), tumor location (Figure 1b), involvement of dominant versus non-dominant cerebral hemisphere (Figure 1c), extent of ablation (Figure 1d), GFAP staining (Figure 1e), and Ki67 index level (Figure 1f). This evidence concerns the gene MKI67 and neoplasm.